23.09.2015 • News

AkzoNobel Doubles Coatings Capacity in Vietnam

AkzoNobel is strengthening its Performance Coatings business in Vietnam, doubling capacity for its powder coatings facility in Dong Nai and opening open a new office for performance coatings in Ho Chi Minh City.

The Dutch company is the largest paints and coatings producer in Vietnam, with four manufacturing locations for both decorative paints and performance coatings and employing more than 800 people.

The new production line in Dong Nai, which will go on stream in November with a 20% increase in its workforce, will also supply customers across Southeast Asia, India, Australia and New Zealand.

"Vietnam has proven to be a strategic market for AkzoNobel in Southeast Asia, and we are strongly committed to expanding our position," said Alan Alex, business manager for the company’s powder coatings business in Southern Asia. "With focused investment, we aim to sustain our high double-digit growth in the domestic market in Vietnam, as well as Southern Asia overall."

Conrad Keijzer, AkzoNobel's executive committee member responsible for Performance Coatings, added: "Vietnam is strongly emerging as a manufacturing base in Asia, which continues to be an attractive growth market. These investments ensure that we are well positioned to meet customer demand going forward."

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read